OncoMatch/Clinical Trials/NCT06733441
A Study of TLN-254 in Participants With Relapsed or Refractory T-cell Lymphoma
Is NCT06733441 recruiting? Yes, currently enrolling (Jun 2026). This Phase 1 trial studies multiple treatments including TLN-254 and TLN-254 for lymphoma.
Treatment: TLN-254 · TLN-254 — The primary purpose of this study is to evaluate the anti-tumor activity of TLN-254 monotherapy in participants with relapsed or refractory T-cell lymphoma.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Non-Hodgkin Lymphoma
Hodgkin Lymphoma
Performance status
ECOG 0–2(Ambulatory, capable of self-care)
Prior therapy
Must have received: systemic treatment
Cohort 1: PTCL that has relapsed after, or not responded to at least one prior systemic treatment regimen
Must have received: systemic treatment
Cohort 2: Relapsed/refractory CTCL which has relapsed after, or not responded to at least two prior systemic treatments
Must have received: antibody-drug conjugate (brentuximab vedotin)
Participants with Anaplastic large cell lymphoma (ALCL) should have received prior brentuximab vedotin treatment.
Cannot have received: systemic anti-cancer treatment
Participants must not have prior systemic anti-cancer treatment less than or equal to (≤) 5 half-lives or 4 weeks prior to study intervention initiation.
Cannot have received: allogeneic stem cell transplant
allogeneic SCT≤90 days prior to study intervention initiation.
Cannot have received: autologous stem cell transplant
autologous SCT ≤60 days prior to study intervention initiation.
Lab requirements
Blood counts
Kidney function
Liver function
Adequate organ function.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Stanford Cancer Institute · Stanford, California
- Washington University School of Medicine · St Louis, Missouri
- Memorial Sloan Kettering Cancer Center · New York, New York
- Sarah Cannon Research Institute · Nashville, Tennessee
Showing up to 5 US sites.
See all sites on ClinicalTrials.gov →Frequently asked questions
Is NCT06733441 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior systemic anti-cancer treatment, allogeneic stem cell transplant, autologous stem cell transplant disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages